TRPV6 and breast carcinoma: Clinical trials are ongoing with a novel TRPV6 inhibitor, in conjunction with standard-of-care therapy, for multiple subtypes of breast cancer, since some current treatments, such as tamoxifen, have been shown to negatively affect the TRPV6 channel as well [85].